Ahead of aducanumab filing, Biogen nabs Pfizer castoff for $75M to address Alzheimer's, Parkinson's symptoms
Biogen believes (not everyone agrees) it has a disease-modifying therapy for Alzheimer’s on the cusp of an FDA approval. Now it’s bringing in an …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
